Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Maj 2025

Genmab — Maj 2025

Planlagt Fastgjort Låst Flyttet Genmab
308 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • B Offline
    B Offline
    bibob
    wrote on sidst redigeret af
    #213

    God morgen. 🙂

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #214

      Dr Falchi on the Safety of Fixed-Duration Epcoritamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma https://www.onclive.com/view/dr-falchi-on-the-safety-of-fixed-duration-epcoritamab-plus-lenalidomide-rituximab-in-r-r-follicular-lymphoma

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #215

        JNJ press release - U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma - https://www.jnj.com/media-center/press-releases/u-s-fda-oncologic-drugs-advisory-committee-votes-in-favor-of-the-benefit-risk-profile-of-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-for-high-risk-smoldering-multiple-myeloma

        1 Reply Last reply
        0
        • N Offline
          N Offline
          NiklasZ
          wrote on sidst redigeret af
          #216

          Så er aktien brudt ud af den nedadgående trend kanal igen. Lad os se om det kan holde denne gang.

          1 Reply Last reply
          0
          • SolsenS Offline
            SolsenS Offline
            Solsen
            wrote on sidst redigeret af
            #217

            Ret interessant melding på Columvi. Stoffet virker tilsyneladende ikke så godt på non-asiatiske pts.

            1 Reply Last reply
            0
            • P Offline
              P Offline
              Plimsoller
              wrote on sidst redigeret af
              #218

              Enig Solsen, og som E L skrev, så vil et nyt fase 3 studie med flere US pts tage år.

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #219

                I guess the moral of the story is if you lost money in the first quarter in biotech, you have plenty of good company. https://x.com/MBbiotech/status/1925123717287346356

                1 Reply Last reply
                0
                • G Offline
                  G Offline
                  gentogen
                  wrote on sidst redigeret af
                  #220

                  Egentlig ret utroligt, at de ikke havde styr på deres geografiske fordeling af patienter, men ifølge oprindelige link fra EL, så havde kun få af de i princippet medvirkende amerikanske klinikker i praksis deltaget

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #221

                    yes, i am surprised too, for such a large firm, and surely they will have been in touch with the FDA during the trial.. here is a bit more:

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #222

                      Asia stymies Columvi's expansion
                      21 May 2025

                      Starglo isn't applicable to a US population, an adcom rules. https://www.oncologypipeline.com/apexonco/node/1334

                      1 Reply Last reply
                      0
                      • L Offline
                        L Offline
                        lahn1
                        wrote on sidst redigeret af
                        #223

                        Har ikke set nærmere på patient grp men kunne Columvi's rekrutterings issues være pga af den samtidige rekruttering i EPCORE DLBCL

                        1 Reply Last reply
                        0
                        • L Offline
                          L Offline
                          lahn1
                          wrote on sidst redigeret af
                          #224

                          De har kun brugt 2 år på STARGLO, og kunne vel nok have fået 3-4 år af FDA til at færdiggøre forsøget. Så den mest oplagte grund er at konkurrence fra ande behandlings regimer bl.a. EPCORE 1+2+4. Er det forkert set at dette er et bragging point for Genmab ?

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #225

                            good thought

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #226

                              by the way, ODAC also voted 5 to 4 against the risk/benefit profile of UGN-102 for bladder cancer ; the company UroGen Pharma -48%....

                              1 Reply Last reply
                              0
                              • SolsenS Offline
                                SolsenS Offline
                                Solsen
                                wrote on sidst redigeret af
                                #227

                                Som jeg læser er det en diskutabel virkning og bivirkningsprofil i non-asiatiske pts mere end en fejl i rekruttering.

                                1 Reply Last reply
                                0
                                • L Offline
                                  L Offline
                                  lahn1
                                  wrote on sidst redigeret af
                                  #228

                                  Det kan også være derfor, men her siger de det lige ud, “We’re sitting here at the US FDA, and 25 patients were enrolled from the US,” said Daniel Spratt, MD, ODAC member and chairman and professor of radiation oncology at University Hospital Seidman Cancer Center, when explaining the reason why he voted no.

                                  “Another word I kept coming back to was ‘sufficient,’ that sponsors should plan to enroll a sufficient number of US participants,” Ravi A. Madan, MD, ODAC member

                                  1 Reply Last reply
                                  0
                                  • G Offline
                                    G Offline
                                    gentogen
                                    wrote on sidst redigeret af
                                    #229

                                    Med andre ord. De har for få patienter til at afgøre, om det er tilfældigheder eller ikke.

                                    1 Reply Last reply
                                    0
                                    • L Offline
                                      L Offline
                                      lahn1
                                      wrote on sidst redigeret af
                                      #230

                                      Har Gmab guvet en update på deres confirmative

                                      1 Reply Last reply
                                      0
                                      • L Offline
                                        L Offline
                                        lahn1
                                        wrote on sidst redigeret af
                                        #231

                                        Conformative trial EPCORE DLBCL-1 var der noget med afslutning blev udsat til 2026 ?

                                        1 Reply Last reply
                                        0
                                        • Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktør
                                          wrote on sidst redigeret af
                                          #232

                                          Godmorgen 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper